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Abstract
Purpose: Leukocyte global DNA methylation levels are currently being considered as biomarkers of cancer susceptibility
and have been associated with risk of several cancers. In this study, we aimed to examine the association between long
interspersed nuclear elements (LINE-1) methylation levels, as a biomarker of global DNA methylation in blood cell DNA, and
renal cell cancer risk.
Experimental Design: LINE-1 methylation of bisulfite-converted genomic DNA isolated from leukocytes was quantified by
pyrosequencing measured in triplicate, and averaged across 4 CpG sites. A total of 328 RCC cases and 654 controls
frequency-matched(2:1) on age(65years), sex and study center, from a large case-control study conducted in Central and
Eastern Europe were evaluated.
Results: LINE-1 methylation levels were significantly higher in RCC cases with a median of 81.97% (interquartile range[IQR]:
80.84–83.47) compared to 81.67% (IQR: 80.35–83.03) among controls (p = 0.003, Wilcoxon). Compared to the lowest LINE-1
methylation quartile(Q1), the adjusted ORs for increasing methylation quartiles were as follows: OR(Q2) = 1.84(1.2022.81),
OR(Q3) = 1.72(1.1122.65) and OR(Q4) = 2.06(1.3423.17), with a p-trend = 0.004. The association was stronger among current
smokers (p-trend,0.001) than former or never smokers (p-interaction = 0.03). To eliminate the possibility of selection bias
among controls, the relationship between LINE-1 methylation and smoking was evaluated and confirmed in a case-only
analysis, as well.
Conclusions: Higher levels of LINE-1 methylation appear to be positively associated with RCC risk, particularly among
current smokers. Further investigations using both post- and pre-diagnostic genomic DNA is warranted to confirm findings
and will be necessary to determine whether the observed differences occur prior to, or as a result of carcinogenesis.
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Introduction
Region-specific hypermethylation and global hypomethylation
of DNA are associated with carcinogenesis [1]. Aberrant DNA
hypermethylation tends to occur in CpG-rich promoter regions
and is associated with transcriptional silencing of genes, such as
tumor suppressor genes [2]. In contrast, genome-wide DNA
hypomethylation occurs primarily in repetitive sequences of DNA,
such as heterochromatic regions and retrotransposons [3]. Several
studies have observed an association between methylation levels of
leukocyte DNA and risk of bladder, breast, and colorectal cancer
[4,5,6,7]. However, the association between global methylation
levels and renal cell cancer (RCC) has not yet been evaluated.
Long interspersed nuclear elements (LINE-1) are non-long-
terminal-repeat (non-LTR) retrotransposons that make up about
17% of the human genome, with ,500,000 elements normally
dispersed throughout the human genome [3,8]. LINE-1 elements
are typically heavily methylated in normal tissues, while LINE-1
hypomethylation has been reported in cancer tissues [9].
Quantification of CpG methylation within LINE-1 elements is
an inexpensive high-throughput assay that has been extensively
used as a proxy of global cytosine methylation (5MeC) levels
[10,11]. Several case-control studies have suggested that LINE-1
methylation levels measured in leukocyte DNA could be a
potential biomarker of cancer susceptibility and genomic instabil-
ity; however, the relationship between LINE1 and other
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biomarkers of global methylation status such as Alu [12] is only
beginning to be explored in large well-designed studies of cancer
risk [13,14,15,16]. Moreover, relationships between methylation
levels in target tissues and non-invasively collected proxy tissue
DNA samples are also not well understood.
The incidence of RCC, the most common malignancy of renal
cancer, varies worldwide [17], with some of the highest rates
occurring in Central and Eastern Europe [18,19]. Cigarette
smoking, obesity, and hypertension are well-established risk factors
for RCC, but these account for only an estimated 50% of cases
[19]. To explore the potential influence of global methylation as a
risk factor for RCC, we compared LINE-1 methylation levels in
leukocyte DNA in a subset of RCC cases and controls enrolled in a
multi-center case-control study. We examined potential effect
modification by common germline polymorphisms and known
RCC risk factors. Lastly, VHL gene inactivation in RCC tumor
tissue is frequently (up to 91%) observed. VHL alteration, through
either promoter hypermethylation or sequence alterations, is
considered an early and frequent event in renal carcinogenesis and
has been used as a biomarker of renal tumor heterogeneity.
Therefore, LINE-1 methylation levels were evaluated among
heterogeneous case subgroups to examine whether risk of having a
specific type of VHL alteration in tumor DNA might be modified
by global methylation levels in genomic DNA.
Results
A majority of study participants were from the Czech Republic,
with a slightly higher proportion among cases. Cases were more
likely than controls to have a higher BMI (p= 0.07) and have a
lower vegetable intake (p= 0.01; Table 1). Distributions of age,
smoking status and self-reported hypertension were comparable
between cases and controls.
Using linear regression models, we evaluated the contribution of
selected participant characteristics hypothesized to be associated
with LINE-1 methylation levels among controls (n = 654; Table 1).
Among controls, males had statistically significantly higher LINE-
1 methylation levels (median= 81.89%) than females (medi-
an = 81.29%; p= 0.0003). Individuals who reported having
hypertension were also associated with statistically significant
higher LINE-1 methylation levels (median= 82.03%) than those
that did not (median= 81.46%; p= 0.04). A significant difference
among centers was also detected among controls (p = 0.01), which
we will adjust for in our models. No distinct trends in LINE-1
methylation levels by age, smoking status, BMI or vegetable intake
were detected among controls. The distribution of LINE-1
%5MeC among cases is also provided in Table 1 for comparison.
Overall, median LINE-1 methylation levels were significantly
higher in RCC cases 81.97% (interquartile range: 80.84–83.47)
compared to 81.67% (interquartile range: 80.35–83.03) among
controls (p = 0.003, Wilcoxon; Table 1). Compared with individ-
uals in the lowest LINE-1 methylation quartile, individuals in the
highest quartile were associated with a 2-fold increased risk of
RCC (p for trend= 0.004; Table 2). The adjusted OR for RCC in
association with a 1% increase in overall LINE-1 methylation was
1.10 (95% CI: 1.03–1.19; p= 0.008). Methylation varied slightly
across each of the four CpG sites sequenced, with the lowest
median %5MeC observed at the fourth locus (median of cases:
78.4%, controls: 78.2%) and the highest levels on the first locus
(median of cases: 85.4%, controls: 84.8%). Compared to controls,
cases had statistically significantly higher %5MeC at each locus (p-
values ranging from ,0.0001 to 0.05, Wilcoxon). Higher %5MeC
at locus 1 demonstrated the strongest association with risk of RCC
(OR=1.24, 95% CI: 1.14–1.35); however, similar upward trends
were observed at the other three loci (locus 2: OR=1.07, 95% CI:
0.99–1.14; locus 3: OR=1.06, 95% CI: 1.00–1.13; locus 4:
OR=1.05, 95% CI: 0.99–1.11).
In analyses stratified by smoking status, the increased risk with
the highest LINE-1 %5MeC quartile (Q4) was more pronounced
among current smokers (ORQ4=6.48, 95% CI: 2.68–15.67;
p-trend ,0.0001) than among former or never smokers
(p-interaction = 0.03; Figure 1). A positive association with RCC
risk was similarly restricted to current smokers across individual
loci (Table S1). To further explore the interaction between
smoking and high LINE-1 %5MeC (Q2–Q4), we conducted a
case-only analysis to ensure that the association was not due to a
control series that was not representative of the study population
with regard to smoking status. Compared to RCC cases that were
never smokers, positive departures from multiplicativity were
observed for RCC cases that were either former (IOR=1.83, 95%
CI: 0.69–4.83) or current smokers (IOR=2.47, 95% CI: 0.91–
6.70; p-trend = 0.06). This would indicate that the relationship of
increased global methylation and RCC is stronger among current
smokers than never smokers. In both analyses, smoking status and
LINE-1 methylation levels appeared to modify the contribution of
the other risk factor. Additional stratified analyses by sex, BMI,
vegetable intake, and self-reported hypertension did not result in
any significant differences (data not shown).
To evaluate whether common variation in selected genes
involved in one-carbon and tobacco metabolism modified the
observed association, we conducted stratified analyses by seven
functional variants in five genes (MTHFR, MTR, TYMS, GSTM1,
and GSTTI). Two genetic variants, MTHFR c.1298A.C and
MTR c.2756A.G, appeared to influence the association between
LINE-1 methylation levels and RCC risk (Table 3). We observed a
strong positive trend between LINE-1 methylation quartiles and
RCC risk among those that carried at least one copy of the
C minor allele of MTHFR c.1298A.C (p-trend= 0.0009;
p-interaction = 0.15). Increased risk with higher levels of LINE-1
methylation was restricted to those with the AA genotype of MTR
c.2756A.G (p-trend= 0.004; p-interaction = 0.19) and was not
significant among those carrying at least one copy of the minor
allele. Neither of these variants demonstrated statistically signifi-
cant main effects, which has been previously published [20].
Because VHL gene inactivation is a frequent early event in RCC
that has been used to define molecular subgroups of renal cancers
[21], we explored whether global methylation was associated with
a particular subset of RCC cases defined by the mechanism
through which VHL gene inactivation in tumor DNA occurs. We
defined RCC subgroups as having VHL gene inactivation through
epigenetic mechanisms (promoter hypermethylation), genetic
mechanisms (changes in coding sequence that would result in an
altered protein (i.e. missense mutations, deletions, insertions, splice
site mutations) or wild type tumors (those without observable VHL
inactivation). Among a subset of RCC cases on which data was
available on VHL promoter methylation or genetic alteration
status in somatic tissue (n = 144), the risk of having an alteration in
VHL increased with increasing quartiles of methylation
(ORQ2= 1.26, 95%CI:0.34–4.64; ORQ3= 1.62, 95%CI:0.42–
6.18; and ORQ4= 2.57, 95%CI:0.68–9.72; p-trend = 0.12).
Although suggestive, more cases are needed to fully evaluate this
association.
Discussion
This study assessed the role of LINE-1 methylation in
peripheral blood DNA as a proxy for global methylation in renal
tumor tissue. In our study, higher LINE-1 %5MeC was associated
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with an increased risk of RCC. Higher LINE-1 %5MeC levels
appeared to be a stronger risk factor for the development of RCC
in current smokers than in former or never smokers. In addition,
results from our study suggest a possible interaction between
LINE-1 methylation and MTHFR c.1298A.Cand MTR
c.2756A.G with RCC.
The association we observed contrasts with what has been
observed in other cancer epidemiologic studies. Global DNA
hypomethylation in tumor tissue has long been observed, but
varies widely within and between types of cancer [7,22]. Global
DNA hypomethylation of leukocyte DNA, measured by %5MeC
content, has been associated with increased cancer risk in several
recent case-control studies, including a large case-control study of
bladder cancer [4,6,7]. In several case-control studies, lower levels
of LINE-1 has been associated with increased risk of testicular
tumors [14], and gastric [13], head and neck [16], and bladder
cancer [15]. However, a small study of breast cancer found no
difference in %5MeC LINE-1 levels between cases and controls,
but a significantly lower %5MeC levels among cases [5]. This
same study also noted that levels of %5MeC and %5MeC LINE-1
(both measured in leukocyte DNA) did not correlate well [5].
Limited data are available on the impact of global DNA
methylation levels in renal tumors and are difficult to compare due
to different methods of assessing methylation. To the best of our
Table 1. LINE-1 Methylation Levels by Characteristics of Study Participants in the Central and Eastern European Renal Cancer
Study.
Cases Controls
N % Average 25% Median 75% N % Average 25% Median 75% p-value
Overall 328 82.13 80.84 81.97 83.47 654 81.74 80.35 81.67 83.03 0.003**
Sex
Male 203 61.9 82.37 81.09 82.19 83.76 396 60.6 81.97 80.44 81.89 83.32
Female 125 38.1 81.73 80.51 81.58 82.65 258 39.4 81.40 80.09 81.29 82.72 0.0003
Age
30–39 10 3.1 82.14 80.57 82.29 82.96 18 2.8 80.98 80.21 80.72 81.34
40–49 46 14 82.25 81.08 82.09 83.24 99 15.1 81.78 80.27 81.46 83.23
50–59 101 30.8 82.40 80.95 82.22 83.83 197 30.1 81.70 80.01 81.67 83.16
60–69 105 32 81.97 80.81 81.72 83.25 209 32 81.68 80.35 81.55 82.98
70+ 66 20.1 81.87 80.52 81.59 83.32 131 20 82.00 80.70 81.98 83.22 0.15
Smoking Status
Never 148 45.4 81.85 80.46 81.83 83.26 284 43.6 81.80 80.37 81.73 83.09
Ex smoker $2 yrs 69 21.2 82.36 81.08 81.96 83.77 156 23.9 82.00 80.79 81.90 83.00
Current 109 33.4 82.38 80.95 82.17 83.53 212 32.5 81.48 79.95 81.38 82.96 0.10
BMI
,25 88 26.8 82.27 80.86 82.26 83.74 213 32.8 81.84 80.25 81.86 83.05
25–30 148 45.1 82.04 80.76 81.96 83.23 292 44.9 81.72 80.35 81.56 83.06
$30 92 28.1 82.13 80.91 81.86 83.43 145 22.3 81.66 80.39 81.63 82.98 0.38
Vegetables (Tertile)
1-Low 90 28.2 82.41 81.02 82.21 83.84 156 24.6 81.58 80.17 81.55 82.98
2-Medium 137 42.9 82.19 80.87 82.05 83.51 234 36.9 81.90 80.39 81.80 83.23
3-High 92 28.8 81.75 80.44 81.66 82.93 244 38.5 81.62 80.11 81.49 82.78 0.99
Self-Reported Hypertension
No 184 56.1 82.14 80.80 81.95 83.53 404 61.8 81.62 80.27 81.46 82.86
Yes 144 43.9 82.11 80.86 82.04 83.42 250 38.2 81.95 80.41 82.03 83.23 0.04
Family History of Cancer
No Cancer 214 65.2 82.15 80.80 82.01 83.65 473 72.3 81.78 80.38 81.66 83.04
Has Kidney Cancer 11 3.4 82.45 81.82 82.29 82.94 8 1.2 82.18 80.97 82.68 84.09
Has other Cancer 103 31.4 82.03 80.81 81.91 83.37 173 26.5 81.63 80.15 81.67 82.97 0.43
Center
Romania 42 12.8 81.37 80.26 81.21 82.23 86 13.2 81.47 80.13 81.36 87.11
Poland 43 13.1 82.59 81.30 82.29 83.87 116 17.7 81.91 80.05 81.66 87.74
Russia 38 11.6 83.05 81.72 82.84 84.54 120 18.4 81.06 79.78 80.90 85.43
Czech Republic 205 62.5 82.01 80.75 81.91 83.24 332 50.8 82.00 80.74 81.98 88.35 0.01
*p-value for potential determinants analysis derived from unadjusted linear regression models among controls only.
**p-value for overall comparison between cases and controls derived from Wilcoxon signed rank test.
doi:10.1371/journal.pone.0027361.t001
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knowledge, data are not available on the correlation between
global methylation status in serum and renal tissue. Among
promoter methylation studies, one study reported that the
promoter methylation state of Wnt genes measured in serum
generally matched that of corresponding renal tumor samples
[23], while the proportion of cases where promoter methylation of
specific cancer-related genes detected in serum matched with
methylation of the same marker in tumors ranged from 0 to 60%
[24]. A few studies have detected increased global methylation in
RCC tissue. Arai et al. reported that genome-wide DNA
methylation profiles, including global hypermethylation, deter-
mined from adjacent normal renal tissue were highly associated
with the aggressiveness of the corresponding RCC [25]. A small
study by Minardi et al. noted a significant increase in global
methylation in tumor tissues with increasing grade of RCC [26].
Two experimental studies have described LINE-1 methylation
status in RCC tissue samples. Chalitchagorn et al. demonstrated
that LINE-1 methylation varied significantly among different
tissue types, but observed no difference in LINE-1 hypomethyla-
tion levels between RCC and renal tissues [9]. Another study
observed an absence of hypomethylation of LINE-1 sequences
across different stages and grades of RCC, which was in contrast
to other urothelial carcinomas [27]. Together, these studies
suggest that RCC may lack the typical association with DNA
methylation observed in other cancers; however, given the varying
assessment methods used, further studies are needed.
To the best of our knowledge, this is the first study to find an
association with higher rather than lower LINE-1 methylation
levels (measured in leukocyte DNA) and cancer risk. Phokaew et
al. observed sporadic instances of hypermethylation in LINE-1 loci
among cancer cell lines[28]. Specific hypermethylation of LINE-1
has also been reported in the abnormal overgrowth and
differentiation of placenta tissue [29]. Although LINE-1 methyl-
ation levels are expected to provide a quick and easy assessment of
global methylation, only a third of genomic DNA methylation is
estimated to occur in repetitive elements [11]. It is also possible
that RCC has an unusual relationship with methylation within
repetitive elements compared to other types of cancer. Lastly, until
our findings are replicated there also remains the possibility that
the association we observed could be due to chance. The observed
association appears somewhat robust and consistent across our
analyses suggesting that these findings were not due to chance;
however, this finding does require replication in a second study
population.
In our evaluation of predictors of LINE-1 methylation levels in
leukocyte DNA, sex was the only characteristic that was strongly
associated with variation in levels. Males had significantly higher
LINE-1 methylation levels than females, which is in agreement
with other studies [14,15,16,30,31,32,33]. Self-reported hyperten-
sion was also associated with higher LINE-1 methylation levels,
but has not been previously evaluated in published studies. Age is
generally considered to be inversely associated with increased
global methylation [34]; however, age was not correlated with
LINE-1 methylation levels in our study or in several previous
studies [9,16,31,32,35,36]. Smoking has been associated with both
promoter hypermethylation and genomic hypomethylation in
tumor DNA [16,37]. However, we did not observe an association
between smoking status and LINE-1 methylation levels in
leukocyte DNA, which is consistent with results from other studies
[15,16,31,32]. The lack of association between LINE-1 methyla-
tion levels in blood with various characteristics in our study was
generally similar to what has been observed in other studies;
however, it should be noted that our controls may not be
representative as they were hospital-based controls.
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Figure 1. Association between LINE-1 methylation levels and risk of RCC stratified by smoking status. Odds ratios and 95% confidence
intervals for the association between LINE-1 methylation levels and RCC, adjusted for sex, age, center, BMI, high blood pressure and vegetable intake.
doi:10.1371/journal.pone.0027361.g001
Table 3. Modification of Association between LINE-1 methylation and RCC risk by selected polymorphisms.
Quartile Range Cases/Controls OR 95% CI Cases/Controls OR 95% CI p interaction
MTHFR- A1298C, Ex8-62A.C, E429A, rs1801131
AA AC/CC
1 74.5–80.3 25/63 1.00 20/93 1.00
2 80.3–81.7 39/65 1.46 0.77–2.78 50/92 2.50 1.35–4.66
3 81.7–83.0 32/70 1.06 0.55–2.06 48/81 2.81 1.50–5.28
4 83.0–88.8 37/65 1.55 0.80–3.01 46/66 3.16 1.65–6.03
P trend = 0.38 0.0009 0.15
MTR- A2756G, Ex26-20A.G, D919G, rs1805087
AA AG/GG
1 74.5–80.3 26/101 1.00 20/56 1.00
2 80.3–81.7 57/99 2.22 1.27–3.89 32/62 1.21 0.60–2.43
3 81.7–83.0 58/90 2.33 1.32–4.10 23/67 0.89 0.42–1.87
4 83.0–88.8 56/90 2.47 1.40–4.37 35/48 1.99 0.95–4.17
P trend = 0.004 0.14 0.19
Adjusted for sex, age, center, tobacco status, BMI, high blood pressure and vegetable intake.
doi:10.1371/journal.pone.0027361.t003
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Smoking has been previously linked to global methylation levels
in tumor tissue [16,37]. Based on data from our study and others,
however, there does not seem to be a well-defined relationship
with regards to genomic DNA isolated from blood [15,16,31,32].
Given the conflicting data on the association between smoking and
methylation levels, it is possible that the effect of smoking
carcinogens on methylation status may be different among
different tissue types. In our data, the risk associated with higher
%5MeC of LINE-1 appears to be enhanced in current smokers,
suggesting an interaction between smoking and LINE-1 hyper-
methylation. It should be noted that previous reports from this
study population did not observe a smoking main effect,
presumably due to some source of control selection bias [38].
However, we did notice that among the three highest quartiles of
LINE-1, current smoking was associated with an increase in RCC
risk compared to never smokers. To deal with the bias, we
conducted a case-only analysis which minimizes any potential
selection bias from the use of hospital-based controls. These results
among cases were similar and confirmed that current smokers who
are heavily methylated within LINE-1 have a higher risk of RCC
than never smokers who are heavily methylated. Several potential
mechanisms for how smoking affects DNA methylation status
exist, such as indirectly through increased systemic inflammation
or double strand-break damage, or directly through the altered
expression of DNA methyltransferases, but the exact mechanism is
poorly understood [39].
As genes involved in one-carbon metabolism have been
associated with global methylation levels and RCC, we conducted
exploratory analyses using available genotype data to assess
whether polymorphisms modified the association between LINE-
1 methylation levels and RCC risk. In the present study, results
from two genetic variants MTHFR c.1298A.Cand MTR c.2756A
.G were suggestive. Other studies of global methylation and
cancer have not observed any noticeable differences in cancer risk
by these variants [4,13,15].
To our knowledge, this is the first study to evaluate LINE-1
methylation levels in leukocyte DNA and risk of RCC. Although a
subset of the full case-control study was selected, this study has
sufficient statistical power to detect associations and they were not
different to the group as a whole. A limitation is that this case-
control study included hospital-based controls and DNA from
cases was collected before treatment yet post-diagnosis. We did not
detect substantial differences in LINE-1 methylation levels by
disease groups among controls, or by stage and grade of cases.
This suggests that disease progression is less likely to have affected
our results. The case-only analysis conducted, eliminated the
potential selection bias that occurs with the use of hospital-based
controls, and supported the association observed in the stratified
analysis. Although LINE-1 methylation levels are considered to be
a proxy for global DNA methylation overall, the two measures are
not entirely interchangeable and could be measuring different
aspects of global methylation. Regardless, many studies have
demonstrated that use of LINE-1 methylation levels in blood can
provide a useful marker for disease and would offer a simple,
noninvasive method to identify individuals at risk for RCC.
In summary, our findings suggest that LINE-1 methylation
levels in leukocyte DNA are positively associated with risk of RCC
and may serve as a biomarker for RCC susceptibility. Investiga-
tions to determine whether global methylation in genomic DNA
reflects epigenetic alterations in renal tissue are necessary to
further elicit the role of epigenetics and RCC. To address these
questions, future studies in prospectively collected DNA samples
will be necessary, as well as studies designed to address the
apparent interaction between methylation status and tobacco
smoking related to RCC risk.
Materials and Methods
Ethics Statement
The study protocol was approved by relevant ethics committees
and institutional review boards of all participating centers, the
International Agency for Research on Cancer (IARC), and the
U.S. National Cancer Institute (NCI) at the U.S. National
Institutes of Health. All study subjects and their physicians
provided written informed consent.
Study Population
The Central and Eastern European Renal Cancer Study
(CEERCC) is a hospital-based case-control study of renal cancer
(1,097 cases and 1,555 controls) that was conducted in seven
centers in Eastern and Central Europe (Moscow, Russia;
Bucharest, Romania; Lodz, Poland; and Prague, Olomouc, Ceske
Budejovice and Brno, Czech Republic). The study population has
been previously described [40]. Briefly, newly diagnosed and
histologically confirmed cases of renal cancer but not renal pelvis
(ICD-0-2 code C64) between the ages of 20 and 79 years were
recruited from 1999 through 2003. Trained medical staff reviewed
medical records and extracted information on date and method of
diagnosis, histological classification, tumor stage and grade.
Eligible controls were chosen from patients admitted to the same
hospital as cases for conditions unrelated to smoking or
genitourinary disorders (except for benign prostatic hyperplasia)
and were frequency-matched to cases on age, sex, and study
center. No single disease made up more than 20% of the control
group. All recruited cases and controls were Caucasian. Response
rates at each center ranged from 90.0 to 98.6% for cases and from
90.3 to 96.1% for controls. Standardized lifestyle and food
frequency questionnaires were administered in person by trained
personnel [38,41].
Blood samples were collected and stored at 280uC and
subsequently shipped to the National Cancer Institute (NCI).
Genomic DNA was extracted from buffy coat by the standard
phenol chloroform method at the NCI laboratory. To evaluate
global methylation, we selected a subset of RCC cases and controls
with a large amount of available DNA ($10 mg) and data on VHL
status using the following matching criteria. Controls were
randomly selected and frequency-matched (2:1) on age (65 years),
sex and study center (if possible) to obtain sufficient power (90% to
detect a minOR of 1.80). All subjects in this study provided written
informed consent. This study was approved by the institutional
review boards at the NCI, International Agency for Research on
Cancer (IARC), and each participating center.
Genotyping
Genotyping assays were performed at NCI’s Core Genotyping
Facility. The following functional single nucleotide polymorphisms
(SNPs) within three genes were considered in this study because of
their role in providing precursors needed for DNA synthesis and
repair, as well as DNA methylation: 5,10 methylenetetrahydrofo-
late reductase (MTHFR; c.1298A.C, c.677C.T), 5-methyltetra-
hydrofolate-homocysteine methyltransferase (MTR; c.2756A.G),
and thymidylate synthetase (TYMS; Ex8+157C.T, Ex8+227A.G).
Glutathione S-transferase mu 1 (GSTM1) and glutathione S-
transferase theta 1 (GSTT1) deletions were also selected because of
previous associations with risk of RCC and their role in phase II
metabolism. Specific experimental methods have been described
previously (http://snp500cancer.nci.nih.gov) [20,42].
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Quantification of LINE-1 Methylation Levels
LINE-1 methylation levels were quantified using a pyrose-
quencing assay at EpigenDx (Worcester, MA) [43,44,45]. Our
assay is designed to examine the methylation status at four CpG
sites in the promoter of the LINE-1 region (GenBank Accession#:
M80343, 2605, 2593, 2590 and 2583 bp from ATG of ORF1)
[16,46]. Briefly, 500 ng of leukocyte DNA was bisulfate treated
and purified using the Zymo DNA Methylation Kit (Zymo
research, Orange, CA). Bisulfate treated DNA was purified and
eluted in 20 mL elution buffer. Each 50ul PCR contained 10X
PCR buffer, 3.0 mM MgCl2, 200 mM dNTPs, 0.2 mM primers,
1.25 U DNA polymerase (HotStar, Qiagen Inc., Alameda, CA)
1.25 U, and ,10 ng of bisulfite converted DNA. The polymerase
was activated by incubation at 95uC for 10 min followed by 34
cycles of 95uC for 15sec, 45uC for 30 sec and 72uC for 30 sec. The
reaction was then allowed to extend for 5 min at 72uC. A universal
biotinylated primer was used in the initial PCR reaction to allow
for isolation of the amplicon, followed by denaturation and release
of a single strand product for pyrosequencing [47]. PCR products
(10 ml) were sequenced using the Pyrosequencing PSQ96 HS
System (Pyrosequencing Qiagen) following the manufacturer’s
instructions (Pyrosequencing Qiagen). Methylation status at each
of 4 loci was analyzed individually as a T/C SNP using QCpG
software (Pyrosequencing Qiagen). Methylation status at all four
loci are averaged together to provide an overall percent 5MeC
status. A sample pyrogram is included as supplementary data
(Figure S1). Percent DNA methylation within LINE-1 was
measured in triplicate.
Statistical Analyses
Triplicate LINE-1 5MeC measurements were averaged togeth-
er. Individual runs with .7.5% bisulfite unconverted cytosine
values and samples with a coefficient of variation (CV).10% were
excluded from our analyses (n = 19). We conducted a sensitivity
analysis, excluding individuals with CV .5%. This exclusion did
not result in a significant difference in risk estimates by at least
10% and thus these subjects remained in the analyses. After these
exclusions, data were available on 982 samples (328 RCC cases
and 654 controls). Differences between cases and controls were
tested for significance using Wilcoxon signed rank tests. To
identify potential determinants of LINE-1 methylation levels and/
or factors that could modify the association between LINE-1
methylation levels and renal cancer risk, linear regression models
were used to evaluate differences among controls in relation to
selected characteristics. The distribution of LINE-1 mean %5MeC
among controls was used to determine cut points for quartiles. To
assess the association between LINE-1 methylation levels and
RCC, logistic regression models, adjusted for the matching factors,
tobacco status, BMI, vegetable intake and self-reported hyperten-
sion, were used to estimate odds ratios(OR) and 95% confidence
intervals(95% CI). Tests for trend were calculated by modeling a
variable coded 0, 1, 2 and 3 for each quartile. We also modeled
LINE-1 as a continuous value. To evaluate potential effect
modification of LINE-1 methylation, stratified analyses by
smoking status, sex, BMI, vegetable intake, self-reported hyper-
tension and selected SNPs were conducted. Common functional
variants within MTHFR, MTR, TYMS, GSTM1, and GSTT1 were
evaluated for association with LINE-1 methylation. The homozy-
gous major allele was coded as the referent group, and the
heterozygous and homozygous minor allele genotypes were
combined together due to small numbers of subjects homozygous
for the minor alleles. A case-only analysis evaluating the
interaction between smoking and LINE-1 methylation levels was
also conducted to provide an estimate of effect modification
(interaction OR: IOR) that would not be influenced by selection
biases among our controls. The IORs represent the departure of
the joint effect of smoking and LINE-1 methylation from that
expected under a multiplicative model on RCC risk. All analyses
were conducted using SAS version 9.1. (SAS Institute, Cary, NC).
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